probucol has been researched along with Disease Exacerbation in 20 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effect of probucol, an antihyperlipidemic drug with potent antioxidant properties, on cataract formation in streptozotocin (STZ)-induced hyperglycemic rats that were given 5% D-glucose as drinking water." | 7.91 | Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats. ( Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K, 2019) |
| " In this work, we studied the effect of treatment with a 1% probucol diet on pulmonary hypertension induced by monocrotaline (MCT) in rats." | 7.70 | Chronic treatment with probucol effectively inhibits progression of pulmonary hypertension in rats. ( Irukayama-Tomobe, Y; Miyauchi, T; Sakai, S, 2000) |
| "We investigated the effect of Probucol in preventing fatty liver in monosodium-L-glutamate (MSG) treated obese mice and control mice fed a high fat diet." | 7.69 | Probucol prevents the progression of fatty liver in MSG obese mice. ( Kondo, M; Sakane, N; Umekawa, T; Yoshida, T; Yoshioka, K, 1995) |
| "A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years." | 5.29 | Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. ( Kajinami, K; Koizumi, J; Mabuchi, H; Nishitsuji, M; Shimizu, M; Takeda, Y, 1996) |
| "We examined the effect of probucol, an antihyperlipidemic drug with potent antioxidant properties, on cataract formation in streptozotocin (STZ)-induced hyperglycemic rats that were given 5% D-glucose as drinking water." | 3.91 | Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats. ( Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K, 2019) |
| " In this work, we studied the effect of treatment with a 1% probucol diet on pulmonary hypertension induced by monocrotaline (MCT) in rats." | 3.70 | Chronic treatment with probucol effectively inhibits progression of pulmonary hypertension in rats. ( Irukayama-Tomobe, Y; Miyauchi, T; Sakai, S, 2000) |
| "We investigated the effect of Probucol in preventing fatty liver in monosodium-L-glutamate (MSG) treated obese mice and control mice fed a high fat diet." | 3.69 | Probucol prevents the progression of fatty liver in MSG obese mice. ( Kondo, M; Sakane, N; Umekawa, T; Yoshida, T; Yoshioka, K, 1995) |
| "The influence of probucol-induced low high-density lipoprotein (HDL) cholesterolemia on the progression of coronary atherosclerosis was studied in 320 patients with angina pectoris or myocardial infarction, 32 patients with probucol 500 mg/day, 288 patients without probucol, who underwent follow-up angiography at intervals of at least 2 years." | 3.69 | [Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis]. ( Harada, S; Hiasa, Y; Hosokawa, S; Kato, S; Kishi, K; Ohtani, R; Takahashi, T; Tanimoto, M, 1997) |
| "Probucol has antioxidant as well as cholesterol-lowering effects." | 2.78 | Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Sakuma, K; Sasaki, H; Shirai, K; Suzuki, Y; Tatsuno, I; Yamaguchi, T; Yamamura, S, 2013) |
| "Probucol has antioxidant and cholesterol-lowering effects." | 2.72 | Probucol delays progression of diabetic nephropathy. ( Endo, K; Ito, Y; Koide, N; Miyashita, Y; Ohira, M; Otsuka, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "Probucol was not found to effect progression regression of femoral atherosclerosis significantly as assessed by quantitative arteriography." | 2.68 | The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. ( Elinder, LS; Holme, I; Johansson, J; Mölgaard, J; Nilsson, J; Nilsson, S; Olsson, AG; Regnström, J; Walldius, G, 1996) |
| " AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants." | 2.44 | AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. ( Eisert, C; Malinin, A; Ong, S; Serebruany, VL, 2007) |
| "Pretreatment with probucol (500 mg/kg, p." | 1.31 | Oxygen radicals mediate the final exacerbation of endothelin-1-induced gastric ulcer in rat. ( Goto, K; Irukayama-Tomobe, Y; Lazaratos, S; Miyauchi, T; Nakahara, A, 2001) |
| "Probucol treatment also significantly reduced high-density lipoprotein (HDL) levels in apoE-deficient mice, but not in LDLR-deficient mice." | 1.31 | Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. ( Chen, Z; Ishibashi, S; Shimano, H; Yamada, N; Yoshikawa, T, 2001) |
| " Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model." | 1.30 | Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997) |
| "A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years." | 1.29 | Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. ( Kajinami, K; Koizumi, J; Mabuchi, H; Nishitsuji, M; Shimizu, M; Takeda, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higashi, K | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Ishii, K | 1 |
| Nakahara, T | 1 |
| Kim, JH | 1 |
| Hong, KW | 1 |
| Bae, SS | 1 |
| Shin, YI | 1 |
| Choi, BT | 1 |
| Shin, HK | 1 |
| Ko, YG | 1 |
| Kim, BK | 1 |
| Lee, BK | 1 |
| Kang, WC | 1 |
| Choi, SH | 1 |
| Kim, SW | 1 |
| Lee, JH | 1 |
| Lee, M | 1 |
| Honda, Y | 1 |
| Fitzerald, PJ | 1 |
| Shim, WH | 1 |
| Endo, K | 2 |
| Saiki, A | 2 |
| Yamaguchi, T | 2 |
| Sakuma, K | 1 |
| Sasaki, H | 2 |
| Ban, N | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Nagumo, A | 1 |
| Ohira, M | 2 |
| Oyama, T | 2 |
| Murano, T | 1 |
| Miyashita, Y | 2 |
| Yamamura, S | 1 |
| Suzuki, Y | 1 |
| Shirai, K | 2 |
| Tatsuno, I | 1 |
| Sawayama, Y | 2 |
| Tatsukawa, M | 1 |
| Okada, K | 2 |
| Maeda, N | 1 |
| Shimizu, C | 1 |
| Kikuchi, K | 1 |
| Hayashi, J | 2 |
| Koide, N | 1 |
| Otsuka, M | 1 |
| Takeyoshi, M | 1 |
| Ito, Y | 1 |
| Kondo, S | 1 |
| Shimizu, M | 2 |
| Urushihara, M | 1 |
| Tsuchiya, K | 1 |
| Yoshizumi, M | 1 |
| Tamaki, T | 1 |
| Nishiyama, A | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Quinn, MT | 1 |
| Lambeth, DJ | 1 |
| Kagami, S | 1 |
| Maeda, S | 1 |
| Ohnishi, H | 1 |
| Furusyo, N | 1 |
| Serebruany, VL | 1 |
| Malinin, A | 1 |
| Eisert, C | 1 |
| Ong, S | 1 |
| Yoshida, T | 1 |
| Yoshioka, K | 1 |
| Sakane, N | 1 |
| Umekawa, T | 1 |
| Kondo, M | 1 |
| Kajinami, K | 1 |
| Nishitsuji, M | 1 |
| Takeda, Y | 1 |
| Koizumi, J | 1 |
| Mabuchi, H | 1 |
| Regnström, J | 1 |
| Walldius, G | 1 |
| Nilsson, S | 1 |
| Elinder, LS | 1 |
| Johansson, J | 1 |
| Mölgaard, J | 1 |
| Holme, I | 1 |
| Olsson, AG | 1 |
| Nilsson, J | 1 |
| Magil, A | 1 |
| Takahashi, T | 1 |
| Hiasa, Y | 1 |
| Harada, S | 1 |
| Hosokawa, S | 1 |
| Kato, S | 1 |
| Tanimoto, M | 1 |
| Kishi, K | 1 |
| Ohtani, R | 1 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Igarashi, J | 1 |
| Aoki, K | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Nagao, S | 1 |
| Kasahara, M | 1 |
| Kusaka, M | 1 |
| Matsuda, J | 1 |
| Ogiso, N | 1 |
| Takahashi, H | 1 |
| Grantham, JJ | 1 |
| Irukayama-Tomobe, Y | 2 |
| Sakai, S | 1 |
| Miyauchi, T | 2 |
| Pfuetze, KD | 1 |
| Dujovne, CA | 1 |
| Lazaratos, S | 1 |
| Goto, K | 1 |
| Nakahara, A | 1 |
| Yoshikawa, T | 1 |
| Shimano, H | 1 |
| Chen, Z | 1 |
| Ishibashi, S | 1 |
| Yamada, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01031667] | Phase 4 | 118 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for probucol and Disease Exacerbation
| Article | Year |
|---|---|
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosi | 2007 |
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
6 trials available for probucol and Disease Exacerbation
| Article | Year |
|---|---|
Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biomarkers; Cilostazol; Coronary Angiograp | 2011 |
Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creati | 2013 |
Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antibodies, Bacterial; Blotting, Western; Carotid Arter | 2003 |
Probucol delays progression of diabetic nephropathy.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Creatini | 2006 |
Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Carotid Artery Diseases; Chlamydophila Inf | 2006 |
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
Topics: Adult; Angiography; Anticholesteremic Agents; Arteriosclerosis; Disease Progression; Female; Femoral | 1996 |
12 other studies available for probucol and Disease Exacerbation
| Article | Year |
|---|---|
Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Cataract; Diabetes Mellitus, Experimental; Disease | 2019 |
Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Brain Injuries; Brain Ischemia; CD11b Antigen; Cerebr | 2014 |
Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Biopsy, Needle; Blotting, Western; D | 2006 |
Probucol prevents the progression of fatty liver in MSG obese mice.
Topics: Animals; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholinesterases; Di | 1995 |
Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary A | 1996 |
Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chronic Disease; Disease Models, Animal; Disease | 1996 |
[Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis].
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery | 1997 |
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor | 1997 |
Effect of probucol in a murine model of slowly progressive polycystic kidney disease.
Topics: Animals; Anticholesteremic Agents; Disease Models, Animal; Disease Progression; Male; Mice; Mice, In | 2000 |
Chronic treatment with probucol effectively inhibits progression of pulmonary hypertension in rats.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Diet; Disease Progression; Hypertension, Pulmonar | 2000 |
Oxygen radicals mediate the final exacerbation of endothelin-1-induced gastric ulcer in rat.
Topics: Adenosine Triphosphate; Aldehydes; Allopurinol; Animals; Catalase; Deferoxamine; Disease Progression | 2001 |
Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cholesterol, HD | 2001 |